50
Participants
Start Date
June 27, 2024
Primary Completion Date
June 30, 2028
Study Completion Date
June 30, 2029
Letermovir
Subjects will receive 14 weeks of letermovir prophylaxis at standard recommended dose follow by CMV-TCIP-directed extended prophylaxis.
CMV T Cell Immunity Panel (CMV-TCIP)
Viracor CMV-TCIP assay to measure how a person's immune system responds to CMV. Viracor CMV-TCIP will be measured monthly, starting at week 14, until positive, then at week 30 and 52.
CMV DNA PCR
Plasma level of CMV DNA PCR will be measured at enrollment and at least weekly through week 30, then at least every 2 weeks through week 52 of transplant if no GVHD or CMV reactivation.
RECRUITING
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Eurofins Viracor
UNKNOWN
University of California, Irvine
OTHER